A Study of the Safety and Effectiveness of Oxazyme in Patients with Hyperoxaluria

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) to degrade food-borne oxalate and prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be increased. Both effects would decrease blood levels of oxalate, and therefore decrease oxalate excretion in the urine.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

This study has been completed

Inclusion Criteria

  • Roux-en-Y gastric bypass hyperoxaluric Calcium oxalate (CaOx) stone subjects or Idiopathic hyperoxaluric CaOx stone subjects
  • Must have or had radio-opaque stones present on x-ray, or a history consistent with the passage of a stone, or stone surgery, or Extracorporeal Shock Wave Lithotripsy (ESWL) in the last 5 years
  • Hyperoxaluria Ox/Cr ratio ≥36 mg/g
  • Must be able to provide written informed consent
  • Must be able to urinate reliably into a collection vessel to measure urine volume
  • May take drugs for the prevention of stone disease, including pyridoxine, thiazides, citrate supplements and allopurinol, as long as there have been no changes in these medications for at least 3 months

Exclusion Criteria

  • Primary hyperoxaluria
  • Use of Oxadrop, Oxabsorb, or other therapies affecting oxalate absorption from the gut, other than stable doses of calcium
  • Pregnancy
  • A negative pregnancy test prior to enrollment 
  • Must practice some form of birth control during the trial
  • On an unstable dose of any other drugs for the prevention of stone disease (i.e., pyridoxine, citrate supplements. etc.)
    • Should have been on a stable dose for at least 3 months prior to randomization

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

John Lieske, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20311336

Mayo Clinic Footer